摘要
目的:分析用恩替卡韦治疗失代偿期乙型病毒性肝炎肝硬化(乙肝肝硬化)的临床效果。方法:选择2015年5月至2019年5月期间在解放军联勤保障部队第988医院接受诊治的失代偿期乙肝肝硬化患者110例作为研究对象。将其随机分为Ⅰ组(60例)和Ⅱ组(50例)。对Ⅱ组患者进行常规治疗。在此基础上为Ⅰ组患者采用恩替卡韦进行治疗。治疗1年后,对比两组患者血清TBil、ALT、ALB的水平、Child-Pugh评分及并发症(包括消化道出血、腹水、感染等)的发生情况。结果:1)Ⅰ组患者治疗的有效率(91.67%)高于Ⅱ组患者治疗的有效率(78%),P<0.05。2)治疗后,Ⅰ组患者血清TBil、ALT的水平、Child-Pugh评分、并发症的发生率均低于Ⅱ组患者,其血清ALB的水平高于Ⅱ组患者,P<0.05。结论:用恩替卡韦治疗失代偿期乙肝肝硬化的效果较好,可显著改善患者的肝功能,降低其并发症的发生率。
Objective:To analyze the clinical effect of entecavir in the treatment of decompensated viral hepatitis B cirrhosis(HBV cirrhosis).Methods:110 patients with decompensated hepatitis B cirrhosis who received treatment in the 988 Hospital of the PLA Joint Logistic Support Force from May 2015 to May 2019 were selected as study subjects.It were randomly divided intoⅠgroup(60 cases)andⅡgroup(50 cases).Conventional therapy in patients withⅡgroup.On this basis forⅠgroup of patients treated with entecavir.After 1 year of treatment,the levels of serum TBil,ALT,ALB,child-pugh score and complications(including gastrointestinal bleeding,ascites,infection,etc.)were compared between the two groups.Results:1)Ⅰefficient(91.67%)than group of patients treatmentⅡgroup of efficient treatment in patients with(78%),P<0.05).2)after treatment,patients withⅠgroup the levels of serum TBil,ALT,Child-Pugh score,the incidence of complications thanⅡgroup of patients,the serum propagated levels higher than theⅡgroups,P<0.05).Conclusion:Entecavir is effective in the treatment of decompensated hepatitis B cirrhosis,which can significantly improve the liver function and reduce t he incidence of complications.
作者
詹春艳
Zhan Chunyan(Department of Infection,Jiaozuo Hospital,988 Joint Logistic Support Fo rce of The Chinese People’s Liberation Army,Jiaozuo Henan 454000)
关键词
恩替卡韦
失代偿期乙肝肝硬化
肝功能
Entecavir
Decompensated hepatitis B cirrhosis
Liver function
